Stem cell project to cure AMD underway

Article

Researchers from University College London (UCL), Moorfields Eye Hospital and the University of Sheffield, UK are launching a pioneering project that plans to use stem cells to cure blindness resulting from age-related macular degeneration.

Researchers from University College London (UCL), Moorfields Eye Hospital and the University of Sheffield, UK are launching a pioneering project that plans to use stem cells to cure blindness resulting from age-related macular degeneration (AMD).

The procedure will generate replacement retinal pigment epithelial (RPE) cells from stem cells in the laboratory. Surgeons will then inject a small patch of new cells, measuring 4 x 6 mm, back into the eye.

An anonymous US donor, frustrated by the US curb on stem cell research, has made the project possible by donating £4 million. The researchers hope that, if successful, the operation could become as routine as cataract surgery.

It is hoped that the first test patients will receive the treatment in just five years time.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.